Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q89375141 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000242.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q89375141 | ||
| 024 | ‡a 0000-0001-7621-4935 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q89375141 | ||
| 100 | 0 | ‡a Russell Hall ‡c researcher ‡9 en | |
| 400 | 0 | ‡a Russell Hall ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab | ||
| 670 | ‡a Author's Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients? | ||
| 670 | ‡a Author's High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease | ||
| 670 | ‡a Author's International Bullous Diseases Group - Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita. | ||
| 670 | ‡a Author's Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy | ||
| 909 | ‡a (orcid) 0000000176214935 ‡9 1 | ||
| 919 | ‡a highdoseintravenousimmunoglobulinasadjuvanttreatmentforgrade4acutecutaneousgraftversushostdisease ‡A High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease ‡9 1 | ||
| 919 | ‡a internationalbullousdiseasesgroupconsensusondiagnosticcriteriaforepidermolysisbullosaacquisita ‡A International Bullous Diseases Group - Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita. ‡9 1 | ||
| 919 | ‡a subacutecutaneouslupuserythematosusanddermatomyositisassociatedwithantiprogrammedcelldeath1therapy ‡A Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy ‡9 1 | ||
| 919 | ‡a doxycyclineandthetreatmentforbullouspemphigoidwhatoutcomesaremostimportanttoourpatients ‡A Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients? ‡9 1 | ||
| 919 | ‡a correlationofiggautoantibodiesagainstacetylcholinereceptorsanddesmogleinsinpatientswithpemphigustreatedwithsteroidsparingagentsorrituximab ‡A Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab ‡9 1 | ||
| 996 | ‡2 RERO|A022989124 | ||
| 996 | ‡2 LC|n 2024041942 | ||
| 996 | ‡2 ISNI|0000000476775064 | ||
| 996 | ‡2 LC|n 2004045361 | ||
| 996 | ‡2 NSK|000057951 | ||
| 996 | ‡2 NUKAT|n 2017016683 | ||
| 996 | ‡2 BNF|14104574 | ||
| 996 | ‡2 LC|n 2021044412 | ||
| 996 | ‡2 DNB|1158137990 | ||
| 996 | ‡2 ISNI|0000000036166214 | ||
| 996 | ‡2 ISNI|0000000025652911 | ||
| 996 | ‡2 LC|n 2015041130 | ||
| 996 | ‡2 NUKAT|n 2016077373 | ||
| 996 | ‡2 BNE|XX1405387 | ||
| 996 | ‡2 LC|n 2007019046 | ||
| 996 | ‡2 NUKAT|n 2013149064 | ||
| 996 | ‡2 BNF|17057916 | ||
| 996 | ‡2 ISNI|0000000459661276 | ||
| 996 | ‡2 CAOONL|ncf11252896 | ||
| 996 | ‡2 CAOONL|ncf11965300 | ||
| 996 | ‡2 ISNI|0000000071449156 | ||
| 996 | ‡2 LC|no2015008700 | ||
| 996 | ‡2 RERO|A006477906 | ||
| 996 | ‡2 J9U|987007459970605171 | ||
| 996 | ‡2 NDL|01149052 | ||
| 996 | ‡2 B2Q|0000367631 | ||
| 996 | ‡2 ISNI|0000000044007483 | ||
| 996 | ‡2 SUDOC|228088194 | ||
| 996 | ‡2 LC|no2010061278 | ||
| 996 | ‡2 LC|no 00098152 | ||
| 996 | ‡2 CAOONL|ncf11620484 | ||
| 996 | ‡2 LC|no2016028174 | ||
| 996 | ‡2 LC|no 98081282 | ||
| 996 | ‡2 NTA|322945003 | ||
| 996 | ‡2 LC|n 89638153 | ||
| 996 | ‡2 ISNI|0000000040886708 | ||
| 996 | ‡2 NTA|412760002 | ||
| 996 | ‡2 J9U|987007376154005171 | ||
| 996 | ‡2 BIBSYS|90371253 | ||
| 996 | ‡2 N6I|vtls000012325 | ||
| 996 | ‡2 LC|no2010087691 | ||
| 996 | ‡2 ISNI|0000000077980490 | ||
| 996 | ‡2 LC|no2018102306 | ||
| 996 | ‡2 BIBSYS|1691037119858 | ||
| 996 | ‡2 NTA|07385204X | ||
| 996 | ‡2 LC|no2014141891 | ||
| 996 | ‡2 ISNI|0000000450470991 | ||
| 996 | ‡2 LC|no2009176274 | ||
| 996 | ‡2 LC|n 88649470 | ||
| 996 | ‡2 ISNI|0000000499462802 | ||
| 996 | ‡2 LC|n 89624692 | ||
| 996 | ‡2 JPG|500225314 | ||
| 996 | ‡2 BIBSYS|1080829 | ||
| 996 | ‡2 LC|nb2014018695 | ||
| 996 | ‡2 CAOONL|ncf10862105 | ||
| 996 | ‡2 ISNI|0000000119492736 | ||
| 996 | ‡2 LC|n 80009260 | ||
| 996 | ‡2 LC|n 85174115 | ||
| 996 | ‡2 BIBSYS|12001597 | ||
| 996 | ‡2 LC|n 88146509 | ||
| 996 | ‡2 LC|n 82006947 | ||
| 996 | ‡2 NUKAT|n 2006108108 | ||
| 996 | ‡2 J9U|987007314873005171 | ||
| 996 | ‡2 RERO|A025824791 | ||
| 996 | ‡2 BIBSYS|90230256 | ||
| 996 | ‡2 LC|nb2008026816 | ||
| 996 | ‡2 ISNI|0000000045516255 | ||
| 996 | ‡2 LC|n 78079732 | ||
| 996 | ‡2 ISNI|0000000038349241 | ||
| 996 | ‡2 BNF|12519963 | ||
| 996 | ‡2 LC|no2008164141 | ||
| 996 | ‡2 ISNI|0000000082524289 | ||
| 996 | ‡2 ISNI|0000000039433664 | ||
| 996 | ‡2 SUDOC|266469353 | ||
| 996 | ‡2 CAOONL|ncf10054631 | ||
| 996 | ‡2 DNB|140544283 | ||
| 996 | ‡2 LC|n 91094954 | ||
| 996 | ‡2 BIBSYS|90634474 | ||
| 996 | ‡2 ISNI|0000000451557677 | ||
| 996 | ‡2 BIBSYS|4063128 | ||
| 996 | ‡2 LC|no 98081797 | ||
| 996 | ‡2 LC|n 99011177 | ||
| 996 | ‡2 DNB|104363061 | ||
| 996 | ‡2 LC|n 89641388 | ||
| 996 | ‡2 RERO|A026859267 | ||
| 996 | ‡2 J9U|987007355372905171 | ||
| 996 | ‡2 ISNI|0000000033426471 | ||
| 996 | ‡2 DNB|1060145871 | ||
| 996 | ‡2 LC|n 85037572 | ||
| 996 | ‡2 ISNI|0000000027781784 | ||
| 996 | ‡2 ISNI|0000000024663344 | ||
| 996 | ‡2 BNF|13493010 | ||
| 996 | ‡2 BIBSYS|9022886 | ||
| 996 | ‡2 RERO|A003342460 | ||
| 996 | ‡2 JPG|500190192 | ||
| 996 | ‡2 NTA|381379396 | ||
| 996 | ‡2 ISNI|0000000036121614 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
